![](images/Newspaper.gif)
Hepatitis B Virus (HBV) Infection in Liver Disease Patients in Mumbai, India with Special Reference to Hepatitis B Surface Antigen (HBsAg) Mutant Detection
19-21
Correspondence
Dr. Supriya Paranjpe,
Department of Microbiology, 5th Floor, Multi-Storey Building,
Seth G. S. Medical College and K. E. M. Hospital, Parel, Mumbai-400 012, India.
Phone : 091-22-24107825, 09987098381, Fax No.: 091 -22- 24164372, E-mail: supriyaparanjpe@rediffmail.com
Objectives: To determine the prevalence of Hepatitis B Surface antigen (HBsAg) in patients attending the Hepatology Out Patient Department (OPD) of a tertiary care hospital and to compare the routinely used HBsAg detection kit with the mutant detection kit to find out the presence of mutants in a given setting.
Materials and Methods: A cross-sectional study was carried out in adult patients with liver disease attending the Hepatology OPD, of a tertiary care hospital in Mumbai, India. Age, gender and clinical history of the patient were recorded. Blood specimen was tested for HBsAg (MicroscreenTM ELISA, Span diagnostics, India) and HBsAg mutants (Hepanostika HBsAg UltraTM ELISA, Biomerieux, France). The samples with discordant results between these two ELISAs were confirmed by Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Polymerase Chain Reaction (PCR) (Cobas TaqmanTM, Roche Molecular Systems, USA).
Results: Seven hundred and eighteen patients were enrolled in the study. The mean age of patients in the study group was 41 years (range 17 to 69 years). Four hundred and ninety seven (69.22%) were males and remaining were females. The prevalence of HBsAg was found to be 17.4%. The positivity amongst the male population was 18.1% which was higher than the female population (15.8%). Of the 718 samples tested, 120 were positive for HBsAg by MicroscreenTM ELISA and 132 were positive by Hepanostika HBsAg ultraTM. Of the 12 discordant samples, HBV DNA was detected in five samples indicating 0.7% prevalence of mutants.
Conclusion: Hepatitis B is prevalent in liver disease patients. The mutant detecting assay is recommended in set-ups where missing HBsAg in patients would have tremendous impact on the outcome such as in blood donors, organ or tissue donors and antenatal screening of mothers. It is also helpful in chronic liver disease patients where the routine HBsAg detection test is negative and the other causes of chronic liver disease have been ruled out. However, it is not recommended for use in routine diagnostic set-ups where high false positivity would lead to over-diagnosis of the condition.